Perceptronix Collaborates With BC Cancer Agency on Early Oral Cancer Detection Project

Vancouver, Canada (ots/PRNewswire) - Perceptronix Medical Inc.
("Perceptronix") today announced its participation in a research
project to detect early oral cancer lesions through a new initiative
inside the BC Oral Cancer Prevention Program. This Program is
bringing together a network of dentists, researchers and technology
companies to develop early screening programs for oral cancer.
Participation in this program is a result of a collaborative research
agreement signed between Perceptronix and researchers with the BC
Cancer Agency.

"The problem with oral cancer," says Dr. Miriam Rosin, Director of
the BC Cancer Agency's Oral Cancer Prevention Program and lead
investigator in the study, "is that there are often no symptoms in
the early stages. And because it is a challenge to identify during
the early stages, it is typically not diagnosed until the cancer has
advanced and it is less responsive to treatment."

The National Cancer Institute of Canada estimates there were 3,000
new oral cancer cases and 1,100 deaths from the disease in 2006.

"During a routine dental exam, there are few clear signs to tell a
dentist whether a sore in the mouth is due to inflammation, infection
or cancer. The tools developed by Perceptronix and LED Dental Inc.
could assist dentists in making those distinctions," added Dr. Rosin.

Patients volunteering for the screening program will be checked
for early cancer using the VELscope(R) fluorescence device developed
by LED Dental Inc. The VELscope will aid in identifying areas that
require further investigation. The next step involves the
ClearCyte(TM) Quantitative Cytology system developed by
Perceptronix. The ClearCyte(TM) system can detect suspicious changes
to DNA using non-invasive oral brushing samples taken by dentists
during a routine check-up; these DNA changes could indicate a cancer
risk. If there is a concern, patients will be referred quickly for
further follow-up and treatment, whether cancer-related or not.

This research has been funded by the National Institute of Dental
and Craniofacial Research and the National Institutes of Health.
Research devices are provided by Perceptronix Medical Inc. and LED
Dental Inc.

About Perceptronix Medical Inc. (www.perceptronix.com)

Perceptronix Medical Inc. (founded in 1999) is a private cancer
diagnostics company based in Vancouver, Canada. Perceptronix
commercializes early cancer detection technologies developed in
partnership with the BC Cancer Agency, a world-leader in cancer care
and research, with a particularly notable track record in pioneering
early cancer detection programs. Perceptronix' products and services
offer an improvement over existing detection and localization
technologies and provide physicians with increased options for
prolonging and improving the quality of patients' lives.

About the BC Cancer Agency (www.bccancer.bc.ca)

The BC Cancer Agency, a part of the Provincial Health Services
Authority, is committed to reducing the incidence of cancer, reducing
the mortality from cancer, and improving the quality of life of those
living with cancer. It provides a comprehensive cancer control
program for the people of British Columbia by working with community
partners to deliver a range of oncology services, including
prevention, early detection, diagnosis and treatment, research,
education, supportive care, rehabilitation and palliative care. The
BC Cancer Foundation raises funds to support research and
enhancements to patient care at the BC Cancer Agency.

About LED Dental Inc. (www.velscope.com)

LED Dental Inc., a wholly owned subsidiary of LED Medical
Diagnostics Inc. (founded in 2003), is headquartered in Vancouver,
British Columbia, Canada. LED Dental develops and markets medical
screening devices based on its proprietary fluorescence visualization
platform to aid in the early diagnosis and treatment of certain
cancerous and precancerous lesions.

This news release is not, and under no circumstances, to be
construed as, an advertisement, solicitation or offering of
securities of Perceptronix Medical Inc. The statements made in this
news release may contain certain forward-looking statements that
involve a number of risks and uncertainties. Actual events or results
may differ from the Company's expectations.

ots Originaltext: Perceptronix Medical Inc.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For further information: Dr. Bojana Turic, Vice President, COO,
Perceptronix Medical Inc., Phone: +1-(604)-707-9037,
info@perceptronix.com; Media Contact: Amanda Smith, BSc, Smith
Biotech, Phone: +1-(778)-846-4116, amanda@smithbiotech.com